A dopamine D2 and D3 receptor partial agonist and 5-HT1A agonist (EC50s = 10, 0.63, and 501 nM, respectively); selective for dopamine D2, D3, and 5-HT1A receptors over a panel of neurotransmitter receptors (Kis = >1000 nM); increases contralateral turning behavior in a 6-OHDA rat model of Parkinson's disease (ED50 = 0.03 mg/kg); reduces amphetamine-induced hyperlocomotion and induces 5-HT1A-mediated flat body posturing and lower lip retraction in rats; dose-dependently increases locomotor activity in an MPTP-induced marmoset model of Parkinson's disease when administered at doses ranging from 0.01-0.3 mg/kg